ArticleHistopathology2007
Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma.
Article in Histopathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.The Cochrane database of systematic reviews · 2009Pooled it
- Therapeutic Effects of Nanoparticles Loaded with Combined Sense and Anti-Sense of EpoR Plasmids to Enhance Angiogenesis.Research square · 2026Article
- Recombinant human erythropoietin therapy in patients with cancer: efficacy, risks and the controversy of EpoR expression.Drugs in context · 2026Review
- Advances in Targeting Growth Factor Signalling in Neuroblastoma and Overcoming Drug Resistance.Cells · 2025Review
- Erythropoietin and Its Angiogenic Activity.International journal of molecular sciences · 2017Review
- Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.Journal of cancer stem cell research · 2017Article
- Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.Oncotarget · 2016Article
- Human rhabdomyosarcoma cells express functional erythropoietin receptor: Potential therapeutic implications.International journal of oncology · 2015Article
- Erythropoietin and cancer: the unintended consequences of anemia correction.Frontiers in immunology · 2014Review
- Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis.International journal of oncology · 2012Article
- Prognostic significance of erythropoietin and erythropoietin receptor in gastric adenocarcinoma.World journal of gastroenterology · 2011Article
- Erythropoietin is involved in angiogenesis in human primary melanoma.International journal of experimental pathology · 2010Article
- Erythropoietin-induced neuroprotection requires cystine glutamate exchanger activity.Brain research · 2010Article
- Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance.Genes & cancer · 2010Article
- Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma.Journal of neuro-oncology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsPrevious studies have shown that increased vascularity is associated with tumour progression in human neuroblastoma (NB). The involvement of erythropoietin (Epo) in tumour angiogenesis has also been reported. The aim of this study was to correlate microvascular density and Epo/Epo-receptor (EpoR) expression in endothelial and tumour cells to the clinical stage of NB. METHODS AND
resultsSpecimens of NB obtained from 20 patients were investigated immunohistochemically by using anti-CD31, anti-Epo and anti-EpoR antibodies. The extent of angiogenesis was found to be up-regulated in advanced disease. In keeping with this observation, Epo/EpoR expression in tumour and endothelial cells, respectively, was also highly correlated with the extent of angiogenesis and higher clinical stage.
conclusionsThe correlation of Epo/EpoR expression with angiogenesis and tumour progression suggests the presence of a loop in the Epo-EpoR system. Epo is secreted by tumour cells and affects vascular endothelial cells via its receptor, promoting tumour angiogenesis in a paracrine manner. Data suggest that Epo represents an important mediator in NB angiogenesis. Understanding the mechanisms of NB angiogenesis provides the basis for a rational approach to the development of antiangiogenic therapy in patients affected by NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.